JPS63104919A - メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤 - Google Patents

メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤

Info

Publication number: JPS63104919A
Authority: JP; Japan
Prior art keywords: menthanylphenol; ethylene oxide; adduct; cancer drug; active ingredient
Prior art date: 1986-10-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP24838686A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0212931B2 (da

Inventor

Seigo Fukushima

福島　清吾

Kazumaro Furuse

一麿古瀬

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-21

Filing date

1986-10-21

Publication date

1988-05-10

1986-10-21 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1986-10-21 Priority to JP24838686A priority Critical patent/JPS63104919A/ja

1988-05-10 Publication of JPS63104919A publication Critical patent/JPS63104919A/ja

1990-03-30 Publication of JPH0212931B2 publication Critical patent/JPH0212931B2/ja

Status Granted legal-status Critical Current

Links

IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 title claims abstract description 20
239000002246 antineoplastic agent Substances 0.000 title claims abstract description 7
229940041181 antineoplastic drug Drugs 0.000 title abstract 4
GHMKDZIUDKBFIR-UHFFFAOYSA-N 4-(5-methyl-2-propan-2-ylcyclohexyl)phenol Chemical compound CC(C)C1CCC(C)CC1C1=CC=C(O)C=C1 GHMKDZIUDKBFIR-UHFFFAOYSA-N 0.000 claims abstract description 16
239000004480 active ingredient Substances 0.000 claims abstract description 5
239000007924 injection Substances 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 4
230000001093 anti-cancer Effects 0.000 abstract description 3
238000001990 intravenous administration Methods 0.000 abstract description 3
FAMJUFMHYAFYNU-JTQLQIEISA-N (4r)-1-methyl-4-propan-2-ylcyclohexene Chemical compound CC(C)[C@@H]1CCC(C)=CC1 FAMJUFMHYAFYNU-JTQLQIEISA-N 0.000 abstract description 2
238000007918 intramuscular administration Methods 0.000 abstract description 2
LFJQCDVYDGGFCH-JTQLQIEISA-N (+)-β-phellandrene Chemical compound CC(C)[C@@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-JTQLQIEISA-N 0.000 abstract 1
239000001293 FEMA 3089 Substances 0.000 abstract 1
239000002994 raw material Substances 0.000 abstract 1
239000013543 active substance Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
239000008103 glucose Substances 0.000 description 3
208000006268 Sarcoma 180 Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000003708 ampul Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
-1 p-menthanyl Chemical group 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
241000779819 Syncarpia glomulifera Species 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000001739 pinus spp. Substances 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
239000000934 spermatocidal agent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940036248 turpentine Drugs 0.000 description 1

Landscapes

Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Epoxy Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP24838686A 1986-10-21 1986-10-21 メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤 Granted JPS63104919A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP24838686A JPS63104919A (ja)	1986-10-21	1986-10-21	メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP24838686A JPS63104919A (ja)	1986-10-21	1986-10-21	メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤

Publications (2)

Publication Number	Publication Date
JPS63104919A true JPS63104919A (ja)	1988-05-10
JPH0212931B2 JPH0212931B2 (da)	1990-03-30

Family

ID=17177331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP24838686A Granted JPS63104919A (ja)	1986-10-21	1986-10-21	メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤

Country Status (1)

Country	Link
JP (1)	JPS63104919A (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009256214A (ja) *	2008-04-11	2009-11-05	Senka Pharmacy:Kk	ポリエチレングリコールの誘導体およびその中間体の製造方法

1986
- 1986-10-21 JP JP24838686A patent/JPS63104919A/ja active Granted

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009256214A (ja) *	2008-04-11	2009-11-05	Senka Pharmacy:Kk	ポリエチレングリコールの誘導体およびその中間体の製造方法

Also Published As

Publication number	Publication date
JPH0212931B2 (da)	1990-03-30

Publication	Publication Date	Title
US6063814A (en)	2000-05-16	Phorbol esters as anti-neoplastic and white blood cell elevating agents
JPH11322596A (ja)	1999-11-24	白金錯体および環状リン酸エステルアミドを含有する抗癌剤
EP0774255A1 (en)	1997-05-21	Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
JPH04505760A (ja)	1992-10-08	Ａｚｔの副作用および毒性からの保護方法
JPS61129129A (ja)	1986-06-17	抗腫瘍剤
KR20010051662A (ko)	2001-06-25	암을 포함한 악성 신생물에 사용하는 항악성종양제
JPH05163148A (ja)	1993-06-29	抗腫瘍剤
JP2005503323A5 (da)	2005-12-22
JPS63104919A (ja)	1988-05-10	メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤
CN106822099A (zh)	2017-06-13	维生素c与苯磺酰胺化合物协同作用的注射用药物组合物
EP0350650A1 (en)	1990-01-17	Therapeutic composition for hepatic encephalopathy
CN102309491B (zh)	2015-06-10	一种替加氟、吉美斯特复方注射液
EP1203585B1 (en)	2005-03-16	Anti-ischemic agent
AU611577B2 (en)	1991-06-13	Use of ubenimex for treating myelodysplastic syndrome
EP0290817A2 (en)	1988-11-17	A Use of oxetanocin for inhibiting HIV
Wilson et al.	1950	Dimethyl ether of d-tubocurarine iodide as a curarizing agent in anaesthesia for thoracic surgery
GB2036554A (en)	1980-07-02	Anthraquinones for use in therapy
CN105663028B (zh)	2018-10-30	一种含去水卫矛醇的经直肠给药双层缓释栓剂
EP0783884A1 (en)	1997-07-16	Preventive and remedy for diarrhea
JPH02121923A (ja)	1990-05-09	４―キノリンカルボン酸誘導体とインターロイキン―２の同時投与による哺乳動物のガン治療
KR100632250B1 (ko)	2006-10-11	비소 화합물을 유효성분으로 하는 항암제
JPH02235813A (ja)	1990-09-18	抗腫瘍剤
JPS6337767B2 (da)	1988-07-27
JPH0616561A (ja)	1994-01-25	抗レトロウイルス剤
IE45653B1 (en)	1982-10-20	Anthraquinones for cancer therapy

JPS63104919A - メンタニルフエノ−ルエチレンオキサイド付加物からなる抗癌剤 - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (2)

Family

ID=17177331

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Also Published As

Similar Documents